ArticleRMD open2024
Window of opportunity in psoriatic arthritis: the earlier the better?
Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Patients' Journey and Burden of Disease Among Patients with Psoriatic Arthritis in Greece: A Cross-Sectional Survey.Mediterranean journal of rheumatology · 2026Article
- Effect of apremilast on entheseal bone damage in psoriasis patients at risk of developing psoriatic arthritis - data from the prospective, interventional EPOS study.Arthritis research & therapy · 2026Article
- Exploring clinical subtypes of Chinese patients with psoriatic arthritis based on cluster analysis: a national registry study (CREPAR V).Clinical rheumatology · 2026Article
- Joint Assessment Matters: Diagnostic and Therapeutic Benefits of Interdisciplinary Psoriasis Care.Advances in therapy · 2026Observational
- Therapeutic Windows Across the Psoriatic Arthritis Spectrum.Rheumatology and therapy · 2026Review
- The role of a multidisciplinary approach in the early and differential diagnosis of inflammatory bowel disease-related spondyloarthritis: insights from a cross-sectional study.Frontiers in medicine · 2026Article
- Clinical and ultrasonographic features preceding a difficult-to-treat phenotype in psoriatic arthritis: a retrospective real-world exploratory cohort study.Frontiers in immunology · 2026Article
- The protocol for a patient-driven online prospective European observational cohort aiming to determine risk factors for the development of psoriatic arthritis among people living with psoriasis: the HIPPOCRATES Prospective Observational Study.Therapeutic advances in musculoskeletal disease · 2026Article
- Navigating the Journey in Psoriatic Arthritis: Matching the Right Patient, the Right Drug, and the Right Time.Journal of clinical medicine · 2025Article
- The Impact of Sex on the Pattern and Clinical Response of Early Psoriatic Arthritis: Real-life Data from the Italian Prospective SIRENA Study.Rheumatology and therapy · 2025Article
- Guselkumab Efficacy in Biologic-Naïve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase 3 Study.Rheumatology and therapy · 2025Article
- Differential Expression of Galectin-1 and Galectin-9 in Immune-Mediated Inflammatory Diseases.International journal of molecular sciences · 2025Article
- Beyond skin deep: total-body positron emission tomography to illuminate systemic inflammation in psoriatic arthritis.Current opinion in immunology · 2025Review
- Navigating Psoriatic Arthritis: Treatment Pathways and Patient-Specific Strategies for Improved Outcomes.Drugs · 2025Review
- Molecular imaging of psoriatic arthritis.Current opinion in rheumatology · 2025Review
- The Impact of IL-17A Inhibition in Rheumatic and Musculoskeletal Diseases: Current Insights and Future Prospects.Rheumatology and therapy · 2025Review
- Identifying characteristics for a cost-effective psoriatic arthritis biomarker test: a development-focused health technology assessment.International journal of technology assessment in health care · 2025Article
- Precision Medicine in Rheumatology: The Role of Biomarkers in Diagnosis and Treatment Optimization.Journal of clinical medicine · 2025Review
- 2023 EULAR Recommendations for the Treatment of PsA: Advances and Pending Issues.Mediterranean journal of rheumatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate whether there is a window of opportunity for psoriatic arthritis (PsA) patients and to assess which patient characteristics are associated with a longer diagnostic delay.
methodsAll newly diagnosed, disease-modifying antirheumatic drug-naïve PsA patients who participated in the Dutch southwest Early PsA cohoRt and had ≥3 years of follow-up were studied. First, total delay was calculated as the time period between symptom onset and PsA diagnosis made by a rheumatologist and then split into patient and physician delays. The total delay was categorised into short (<12 weeks), intermediate (12 weeks to 1 year) or long (>1 year). These groups were compared on clinical (Minimal Disease Activity (MDA) and Disease Activity index for PSoriatic Arthritis (DAPSA) remission) and patient-reported outcomes during 3 years follow-up.
results708 PsA patients were studied of whom 136 (19%), 237 (33%) and 335 (47%) had a short, intermediate and long total delay, respectively. Patient delay was 1.0 month and physician delay was 4.5 months. Patients with a short delay were more likely to achieve MDA (OR 2.55, p=0.003) and DAPSA remission (OR 2.35,p=0.004) compared with PsA patients with a long delay. Patient-reported outcomes showed numerical but non-significant differences between the short and long delay groups. Female patients and those presenting with enthesitis, chronic back pain or normal C-reactive protein (CRP) had a longer delay.
conclusionsIn PsA, referral and diagnosis within 1 year is associated with better clinical outcomes, suggesting the presence of a window of opportunity. The most gain in referral could be obtained in physician delay and in females, patients with enthesitis, chronic back pain or normal CRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.